Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical, boosting the price target to $38.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason Gerberry has given his Buy rating due to a combination of factors tied mainly to Teva’s TL1a program in inflammatory bowel disease, which continues to show a compelling efficacy and dosing profile. The new Phase 2 maintenance results for duvakitug indicate that patients who initially responded largely preserved their benefit, and the remission and endoscopic response rates not only held up but improved versus the induction phase, all while shifting to a more convenient once‑monthly regimen that is aligned with other leading TL1a therapies.
Gerberry also highlights that these data alleviate prior concerns about durability and dosing frequency, suggesting duvakitug will not be disadvantaged versus late‑stage competitors and may even offer best‑in‑class outcomes despite Merck’s expected first‑mover edge. Reflecting the stronger outlook, he lifts his peak sales estimate for duvakitug to about $3 billion and modestly increases his 2027 valuation multiple, which together support a higher price objective of $38 per share and underpin his continued Buy recommendation on Teva.
Gerberry covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Teva Pharmaceutical, and Eli Lilly & Co. According to TipRanks, Gerberry has an average return of 16.7% and a 61.22% success rate on recommended stocks.
In another report released on February 10, Goldman Sachs also maintained a Buy rating on the stock with a $45.00 price target.